Get the Stockscreener App
2.15
1.90%
0.04
Neuraxis Inc stock is traded at $2.15, with a volume of 51,963.
It is up +1.90% in the last 24 hours and down -1.38% over the past month.
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
See More
Previous Close:
$2.11
Open:
$2.2
24h Volume:
51,963
Relative Volume:
2.30
Market Cap:
$15.23M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-2.6655
EPS:
-0.8066
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
-1.38%
6M Performance:
-28.33%
1Y Performance:
-32.39%
1-Day Range:
$2.00
$2.30
1-Week Range:
$2.00
$2.30
52-Week Range:
$1.99
$3.78
Neuraxis Inc Stock (NRXS) Company Profile
Name
Neuraxis Inc
Sector
Industry
Phone
(812) 689-0791
Address
11550 North Meridian Street, Suite 325, Carmel
Compare NRXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXS
Neuraxis Inc
|
2.15 | 15.23M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Neuraxis Inc Stock (NRXS) Latest News
NeurAxis, Inc. (NASDAQ:NRXS) Q4 2024 Earnings Call Transcript - MSN
NeurAxis (NASDAQ:NRXS) Trading Down 0.9% – Should You Sell? - Defense World
NeurAxis Stock Gains Post Q4 Earnings And Revenue Growth - Barchart
NeurAxis Stock Gains Post Q4 Earnings and Revenue Growth - Zacks Investment Research
NeurAxis (NASDAQ:NRXS) & BioLife Solutions (NASDAQ:BLFS) Head-To-Head Analysis - Defense World
NeurAxis, Inc. Reports Strong Q4 Growth Amid Challenges - TipRanks
NeurAxis revenues increase 43% to USD 761K in Q4 2024 - Medical Buyer
NeurAxis, Inc. Reports Strong Q4 2024 Results - TipRanks
Earnings call transcript: Neuraxis Q4 2024 sees revenue growth, loss narrows - Investing.com Canada
Earnings call transcript: Neuraxis Q4 2024 sees revenue growth, loss narrows By Investing.com - Investing.com South Africa
NeurAxis Better on Q4 Results - Baystreet.ca
NeurAxis, Inc. Reports 43% Revenue Growth in Q4 2024 and Significant Milestones Achieved - Nasdaq
NeurAxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues - GlobeNewswire
Earnings Scheduled For March 20, 2025 - Benzinga
NeurAxis, Inc. Set to Announce Fourth Quarter and Fiscal Year 2024 Financial Results on March 20, 2025 - Nasdaq
NeurAxis to Host Fourth Quarter and Full Year 2024 Results and Business Update Call on Thursday, March 20, 2025 - GlobeNewswire
NRXS stock touches 52-week low at $1.99 amid market challenges By Investing.com - Investing.com South Africa
NRXS stock touches 52-week low at $1.99 amid market challenges - Investing.com
Vagus Nerve Stimulators Market Detailed In New Research Report - openPR
NeurAxis (NASDAQ:NRXS) Stock Price Down 2.8% – Here’s Why - Defense World
Chronic Idiopathic Constipation Clinical Trials and Pipeline - openPR
Critical Contrast: NeurAxis (NASDAQ:NRXS) & Zynex (NASDAQ:ZYXI) - Defense World
Vagus Nerve Stimulators Market Witness Growth: Booming Demand, - openPR
Analyzing NeurAxis (NASDAQ:NRXS) and Masimo (NASDAQ:MASI) - Defense World
End Of January 2025 Portfolio Review - substack.com
FDA Clears NeurAxis’ Self-Inflating Balloon Device - MPO-mag
Financial Contrast: NeurAxis (NASDAQ:NRXS) versus ENDRA Life Sciences (NASDAQ:NDRA) - Defense World
NeurAxis, Inc. Announces New Medical Policy Coverage with a Prominent Insurer for over Five Million Lives Across Multiple States - Marketscreener.com
UPDATENeurAxis Announces New Medical Policy Coverage with a Prominent Insurer for Over Five Million Lives Across Multiple States - The Manila Times
NeurAxis Expands IBS Treatment Coverage to 51M Lives, Targets Youth Market with Novel Device - StockTitan
NeurAxis Announces New Medical Policy Coverage with Molina Healthcare for Over Five Million Lives Across Multiple States - The Manila Times
NeurAxis Announces New Medical Policy Coverage with Molina - GlobeNewswire
NeurAxis Expands Coverage for FDA-Cleared IBS Pain Device to 51M Lives with Molina Deal - StockTitan
NeurAxis announces Q4 preliminary unaudited revenues were about $800 thousand - MSN
Vagus Nerve Stimulators Market Growth in Future Scope 2025-2032 - openPR
Critical Analysis: Precision Optics (NASDAQ:POCI) & NeurAxis (NASDAQ:NRXS) - Defense World
Vaso Corporation Announces Executive Leadership Appointments & Names New Vice Chairman to the Board of Directors - The Manila Times
NeurAxis Inc. Issues Letter to Shareholders - GlobeNewswire
NeurAxis IB-Stim Reaches Major Milestone: Insurance Coverage Surges to 51 Million Lives, FDA Expands Age Range - StockTitan
AAR Corporation (NYSE: AIR) Issues Press Release and Slide Presentation on Q2 2025 Financial Results - Defense World
Amplitude Healthcare Acquisition (OTCMKTS:AMHCU) Announces Positive Preliminary Data from Jasper Therapeutics, Inc. BEACON Phase 1b/2a StudyOn January 8, 2025, Jasper Therapeutics, Inc. released a press release detailing encouraging preliminar - Defense World
NeurAxis, Inc. Reports Strong Preliminary Unaudited Fourth Quarter 2024 Results - Defense World
NeurAxis Inc. Announces Strong Preliminary Unaudited Fourth Quarter 2024 Results; Revenues Increased 50% Year-Over-Year - Marketscreener.com
Everything Blockchain Inc. Announces Letter to Shareholders from CEO - The Manila Times
NeurAxis Inc. Announces Strong Preliminary Unaudited Fourth - GlobeNewswire
NeurAxis Q4 Revenue Surges 50% as IB-Stim Coverage Reaches 45 Million Lives - StockTitan
NeurAxis (NASDAQ:NRXS) Shares Down 4.1% – What’s Next? - Defense World
Model N Appoints New Chief Executive Officer, Bret Connor - The Manila Times
Neuraxis Inc Stock (NRXS) Financials Data
There is no financial data for Neuraxis Inc (NRXS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.00%
Cap:
|
Volume (24h):